Edwards starts US SFA (superficial femoral artery) trials for LifeStent:
This article was originally published in Clinica
Edwards Lifesciences has begun a US trial to assess its self-expanding stent, LifeStent NT, as a treatment for peripheral vascular disease. The RESILIENT study, which will involve around 220 patients at up to 25 medical centres throughout the country, differs from similar investigations because it is intended to demonstrate superiority, rather than equivalence, of the device over angioplasty in treating blockages in the superficial femoral artery (SFA) and popliteal artery, says the Irvine, California firm. The LifeStent system comprises a helical structural scaffold designed to withstand the continual bending and flexing experienced in the SFA. The company, which is also looking to CE-mark the product in Europe for the peripheral vascular disease indication, has already received US market clearance to use the device for treating biliary obstructions.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.